Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

How much enzyme does it take to erase a filler?

NCT ID NCT01722916

Knowledge-focused Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates the correct dose of hyaluronidase, an enzyme that breaks down hyaluronic acid fillers, to safely and effectively remove them. Researchers will inject increasing amounts of hyaluronidase into healthy adults until the filler is no longer detectable. The goal is to establish a standard dosing guide for doctors, reducing guesswork and improving safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyaluronidase
What this could lead to
If successful, this could provide clear dosing guidelines for safely dissolving unwanted hyaluronic acid fillers.
What could go wrong
This is a very small early-phase pilot study with only 5 participants, so results may not apply to everyone. Risks include allergic reactions or incomplete filler removal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Oct 2012

Finished

Feb 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 and over * The subjects are in good health * The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator Exclusion Criteria: * Under 18 years of age * Pregnancy or Lactation * Subjects who are unable to understand the protocol or to give informed consent * Subjects with mental illness * Recent Accutane use in the past 6 months * Subjects prone to hypertrophic and keloidal scarring * Subjects with tattoos and/or scars on upper medial arms (the treatment area) * Subjects with known hypersensitivity to hyaluronic acid

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug safety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug safety

Contacts and locations

Locations

  • Northwestern University Department of Dermatology

    Chicago, Illinois, 60611, United States